Mike Grey is executive chairman and a founder of Reneo Pharmaceuticals. He also serves as executive chair of Amplyx Pharmaceuticals and Spruce Biosciences, and is venture partner at Pappas Ventures. Previously, he founded and was president and CEO at Lumena Pharmaceuticals, a company developing treatments for pediatric and adult orphan diseases, until its acquisition by Shire.
Mike has more than 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies. Past positions include executive chair of Ziarco Pharma (acquired by Novartis), president and CEO of Auspex Pharmaceuticals, president and CEO of SGX Pharmaceuticals (acquired by Eli Lilly), president and CEO of Trega Biosciences (acquired by Lion Bioscience) and president of BioChem Therapeutic. For approximately 20 years, Mike served in various roles with Glaxo and Glaxo Holdings plc, culminating in his position as vice president, corporate development and head of international licensing.
Mike serves on the board of directors of BioMarin Pharmaceutical, Biothera Pharmaceuticals, Horizon Pharma and Mirati Therapeutics.